Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)‘s stock had its “buy” rating reissued by investment analysts at Cowen and Company in a note issued to investors on Wednesday. They presently have a $112.00 price objective on the biopharmaceutical company’s stock. Cowen and Company’s price target would indicate a potential upside of 81.73% from the company’s current price.

Several other equities research analysts have also weighed in on the stock. Wells Fargo & Company reiterated an “outperform” rating on shares of Intercept Pharmaceuticals in a research note on Wednesday, September 13th. Jefferies Group LLC started coverage on shares of Intercept Pharmaceuticals in a research note on Monday, July 10th. They set a “buy” rating and a $275.00 price objective on the stock. Cantor Fitzgerald reiterated an “underweight” rating and set a $69.00 price objective on shares of Intercept Pharmaceuticals in a research note on Wednesday, September 13th. Bank of America Corporation dropped their price objective on shares of Intercept Pharmaceuticals from $102.00 to $73.00 and set an “underperform” rating on the stock in a research note on Friday, October 13th. Finally, Robert W. Baird reiterated an “outperform” rating and set a $332.00 price objective on shares of Intercept Pharmaceuticals in a research note on Wednesday, September 13th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $153.76.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share for the quarter, topping the consensus estimate of ($3.48) by $0.59. The firm had revenue of $41.33 million for the quarter, compared to analyst estimates of $36.95 million. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. Intercept Pharmaceuticals’s quarterly revenue was up 697.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($3.59) earnings per share.

ILLEGAL ACTIVITY NOTICE: “Intercept Pharmaceuticals, Inc. (ICPT) Earns “Buy” Rating from Cowen and Company” was first reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/11/01/intercept-pharmaceuticals-inc-icpt-earns-buy-rating-from-cowen-and-company.html.

In related news, CEO Mark Pruzanski sold 1,532 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $58.87, for a total transaction of $90,188.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Lisa Bright sold 253 shares of the firm’s stock in a transaction that occurred on Friday, August 25th. The stock was sold at an average price of $111.31, for a total transaction of $28,161.43. Following the sale, the insider now owns 23,324 shares of the company’s stock, valued at $2,596,194.44. The disclosure for this sale can be found here. Insiders have sold 4,069 shares of company stock worth $325,974 in the last quarter. Company insiders own 4.50% of the company’s stock.

A number of large investors have recently modified their holdings of ICPT. Balyasny Asset Management LLC bought a new stake in Intercept Pharmaceuticals during the second quarter worth approximately $13,766,000. Vanguard Group Inc. boosted its holdings in Intercept Pharmaceuticals by 4.5% during the second quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock worth $160,797,000 after buying an additional 57,149 shares in the last quarter. State Street Corp boosted its holdings in Intercept Pharmaceuticals by 7.3% during the first quarter. State Street Corp now owns 805,550 shares of the biopharmaceutical company’s stock worth $91,110,000 after buying an additional 54,523 shares in the last quarter. First Trust Advisors LP boosted its holdings in Intercept Pharmaceuticals by 17.0% during the second quarter. First Trust Advisors LP now owns 287,411 shares of the biopharmaceutical company’s stock worth $34,797,000 after buying an additional 41,856 shares in the last quarter. Finally, Quantitative Investment Management LLC bought a new stake in Intercept Pharmaceuticals during the second quarter worth approximately $3,728,000. Hedge funds and other institutional investors own 82.81% of the company’s stock.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.